Ldl-lowering therapies
Ldl-lowering therapies has been studied in 2 papers since 2023: none in people yet, 2 reviews; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 31, 2026: “Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention”.
2 papers study it1 findingUpdated
1 new paper in 30 daysSee all 2 papers on ldl-lowering therapies
What did studies of ldl-lowering therapies find?
1Studies of ldl-lowering therapies measured one outcome, cardiovascular events.
Cardiovascular events
downin humans1
1 study
Cardiovascular events
downin humans1
Ldl-lowering therapies decrease cardiovascular events in humans.
“LDL-lowering therapies have established cardiovascular outcome efficacy.”
Review
Frontiers in cardiovascular medicine
Latest
1 paper in 12 monthsFrontiers in Cardiovascular Medicine
Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention
ReviewMechanisms